Deadly fungal infections are becoming resistant to common treatments, but a team of researchers from USC and from France have found a potential innovative solution.
Each year, invasive fungal infections sicken an estimated 2 million people worldwide and kill nearly 800,000 – but a team of international scientists have discovered a new approach for antifungal drug treatments.
Researchers from USC and France identified that a gene-regulating protein, Bdf1, is critical for the survival of the pathogenic fungus, Candida albicans.
“We have shown that Bdf1 is an important new target for drug design,” said Charles McKenna, a senior author of the study who is a professor of chemistry and pharmaceutical sciences in the USC Dornsife College of Letters, Arts and Sciences. “Our findings show that compounds that bind to this target will disrupt the growth of the fungus, opening the way to novel drug treatments for fungal disease.”
The French scientists who led the study with McKenna were Jérôme Govin and Carlo Petosa, both at the University of Grenoble Alpes.
Rising health threat
The fungus, C. albicans, is an aggressive pathogen that in healthy individuals is normally held in check by the immune system. However, people with a weakened immune system, including patients who have cancer, HIV or autoimmune diseases, are susceptible to the infection, which can be life-threatening, McKenna said.
The team’s findings, published on May 18 in the journal Nature Communications, may prove timely. Fungal infections such as candidiasis are increasingly resistant to drug treatments.
Each year, an estimated 46,000 patients in the United States become infected with invasive candidiasis, according to the Centers for Disease Control and Prevention.
“When susceptible people develop candida infections, the fungus may enter the bloodstream. If treatment is unsuccessful, it has a very high mortality rate – in the 40 percent range,” McKenna said. “We have a very limited number of drugs that are effective in treating such systemic infections. Unfortunately, like many other pathogens, C. albicans is increasingly resistant to the few available drugs, raising the stakes for patients, and fresh approaches are urgently needed.”
The Latest on: Antifungal drug treatments
- Global Antifungal Drugs Market Size – Novartis, Pfizer, Sanofi, Merck on December 9, 2018 at 2:58 am
Market Intelligence Data has launched a report on the Antifungal Drugs Market that predicts future market trends and current market trends. It includes analytic data of the Antifungal Drugs Market abo... […]
- Fungal Eye Infection Pharmaceutical and Healthcare Analysis Information on December 5, 2018 at 1:27 am
The treatment of fungal infections is limited by lack of innovative therapies due to the low rate of antifungal and antibiotic drug development and costly clinical trials. Thus, the government had cha... […]
- Anti-fungal Drugs Market Report on the Product Type That Is Expected to Dominate the Market During 2018-2023 on November 30, 2018 at 1:31 pm
Anti-fungal Drugs Market report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Anti-fungal Drugs market landscape and its growth prospe... […]
- Antifungal infection Therapeutics Market by Technology, Application & Geography Analysis & Forecast to 2023 on November 30, 2018 at 10:20 am
Antifungal drugs are used to treat infections caused by fungus and to prevent the development of fungal infections in patients with weakened immune systems. Considered to be one of the most acclaimed ... […]
- FDA approves new drug to treat travelers' diarrhea on November 15, 2018 at 4:00 pm
The FDA granted Aemcolo a Qualified Infectious Disease Product (QIDP) designation. QIDP designation is given to antibacterial and antifungal drug products that treat serious or life-threatening infect... […]
- Antifungal Drugs Market Worldwide Major Trend Outlook 2016 to 2024 on November 9, 2018 at 9:31 am
The antifungal drugs market is a very successful over-the-counter drug segment, in which robust generic competition is slated to rake in almost 65% to 70% of total market revenues in the near future. ... […]
- Off-patent drug appears promising as broad-spectrum antifungal on October 31, 2018 at 10:40 am
"There are currently only three major classes of antifungal drugs used in the clinic and several pathogenic fungi are resistant to them, so there is an urgent need to identify compounds that have nove... […]
- Cancer Drug and Antidepressants Provide Clues for Treating Fatal Brain-Eating Amoeba Infections on September 13, 2018 at 11:10 am
Other than trial-and-error with general antifungal medications, there are no treatments for the infection. Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of Califor... […]
- Worldwide emergence of resistance to antifungal drugs challenges human health and food security on May 17, 2018 at 11:09 am
1 MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London W2 1PG, UK. 2 Department of Biointeractions and Crop Protection, Rothamsted Research, Harp... […]
- Resistance to antifungal drugs could lead to disease and global food shortages on May 17, 2018 at 11:02 am
Growing levels of resistance to antifungal treatments could lead to increased disease outbreaks and affect food security around the world. An international team, led by researchers from Imperial Colle... […]
via Google News and Bing News